ICER values Entresto 17% below list price
The Institute for Clinical and Economic Review (ICER) released a value assessment report for congestive heart failure (CHF) therapy Entresto sacubitril/valsartan from Novartis AG (NYSE:NVS; SIX:NOVN). The non-profit concluded the annual value-based price of Entresto should be $3,779, 17% below its list price of $4,560.
ICER predicted nearly 2 million Entresto prescriptions would be written over the next five years, which it said would create an excessive cost burden on healthcare systems. The institute concluded that Entresto is cost-effective at its list price for individual patients, but the large number of anticipated prescriptions would push costs over a five-year annualized budget threshold of $904 million per year that would trigger policy actions to manage affordability. ...